C
Connie L. Davis
Researcher at University of Washington
Publications - 138
Citations - 10222
Connie L. Davis is an academic researcher from University of Washington. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 57, co-authored 138 publications receiving 9584 citations. Previous affiliations of Connie L. Davis include Beth Israel Deaconess Medical Center & Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
Ajit P. Limaye,Lawrence Corey,Lawrence Corey,David M. Koelle,David M. Koelle,Connie L. Davis,Michael Boeckh,Michael Boeckh +7 more
TL;DR: Ganciclovir-resistant cytomegalovirus is an important cause of late morbidity among D+/R- transplant recipients who have had lengthened exposure to gancic Lovir and have received highly potent immunosuppression and strategies to reduce this complication are warranted.
Journal ArticleDOI
Kidney Transplantation as Primary Therapy for End-Stage Renal Disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) Conference
M. Abecassis,Stephen T. Bartlett,Allan J. Collins,Connie L. Davis,Francis L. Delmonico,John J. Friedewald,Rebecca Hays,Andrew Howard,Edward R. Jones,A. B. Leichtman,Robert M. Merion,Robert A. Metzger,Francoise Pradel,Eugene J. Schweitzer,Ruben L. Velez,Robert S. Gaston +15 more
TL;DR: With implementation of early education, referral to a transplant center coincident with creation of vascular access, timely transplant evaluation, and identification of potential living donors, early transplantation can be an option for substantially more patients with chronic kidney disease.
Journal ArticleDOI
Evaluation of Intravenous Immunoglobulin as an Agent to Lower Allosensitization and Improve Transplantation in Highly Sensitized Adult Patients with End-Stage Renal Disease: Report of the NIH IG02 Trial
Stanley C. Jordan,Stanley C. Jordan,Dolly B. Tyan,Don M. Stablein,Matthew McIntosh,Steve Rose,Ashley Vo,Mieko Toyoda,Connie L. Davis,Ron Shapiro,Deborah Adey,Dawn S. Milliner,Ralph J. Graff,Robert W. Steiner,Gaetano Ciancio,Shobah Sahney,Jimmy A. Light +16 more
TL;DR: It is concluded that IVIG is better than placebo in reducing anti-HLA antibody levels and improving transplantation rates in highly sensitized patients with ESRD awaiting kidney transplants.
Journal ArticleDOI
Living-Donor Kidney Transplantation: A Review of the Current Practices for the Live Donor
TL;DR: Living donation as practiced for the past 50 yr has been safe with minimal immediate and long-term risk for the donor, but the future experience may not be the same as the authors' society is becoming increasingly obese and developing associated health problems.
Journal ArticleDOI
Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK)
TL;DR: The consensus was that Regional Review Boards (RRB) should determine listing for SLK, as with other MELD exceptions, with automatic approval for: End‐stage renal disease with cirrhosis and symptomatic portal hypertension or hepatic vein wedge pressure gradient ≥ 10 mm Hg.